Interleukin
Serum biomarkers 'clearly separate' COVID-19 from classic cytokine storm syndromes
Increased interleukin‐1Ra and IL‐8 serum levels, and other biomarker profiles, “clearly separate” COVID-19 from macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis, according to data published in Arthritis & Rheumatology.
IL-7 safe for critically ill patients with COVID-19
Interleukin-7 can be safely given to critically ill patients with COVID-19 without fear of worsening inflammation or pulmonary injury, according to findings published in JAMA Network Open.
Ixekizumab outperforms adalimumab for joint, skin improvement in PsA
Ixekizumab demonstrated significantly greater joint and skin improvement, through week 52, than adalimumab among patients with psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.
Deeper disease insight signals 'exciting time' for PsA drug pipeline
Patients with psoriatic arthritis have much to be hopeful about, with understanding of the disease increasing and an expanded range of treatment options available, according to a presenter at the 2020 Rheumatology Nurses Society Annual Conference.
Sarilumab safe, effective in severe COVID-19 with minor lung consolidation
Although sarilumab fared no better than the standard of care regarding clinical improvement and mortality among patients with severe COVID-19, the drug was linked to faster recovery among patients with minor lung consolidation.